- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03483038
A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Alexandra Mueller
- Phone Number: (352) 273-9785
- Email: PMO@cancer.ufl.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32608
- University of Florida
-
Orlando, Florida, United States, 32806
- Orlando Health UF Health Cancer Center
-
Tallahassee, Florida, United States, 32308
- Tallahassee Memorial Health Care
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Melvin and Bren Simon Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must be at least 18 years of age.
- A new clinical diagnosis of resectable or borderline resectable, previously untreated pancreatic adenocarcinoma confirmed by pathologic specimen evaluation
- No clinical evidence of metastatic disease
- Potentially resectable local disease, as confirmed by CT or MRI of the abdomen
- ECOG performance status of 0 or 1
- Any biliary obstruction must have been treated.
- Subjects with known or suspected Gilbert's disease must be formally tested for UGT1A1*28 with results available to study team prior to treatment initiation
Adequate organ function; as defined by:
i. Hematologic-
- ANC > 1,500 cells/μl without the use of hematopoietic growth factors; and
- Platelet count > 100,000 cells/μl; and
Hemoglobin > 9 g/dL (blood transfusions are permitted for patients with hemoglobin levels below 9 g/dL)
ii. Hepatic-
- Serum total bilirubin within 1.5 x upper limit of normal (ULN) for the institution, with a trend downwards (biliary drainage is allowed for biliary obstruction),
AST and ALT less than or equal to 2.5 x ULN
iii. Renal- Serum creatinine less than or equal to 1.5 x ULN
iv. Cardiac- Normal ECG or ECG without any clinically significant findings as defined by the treating physician
- Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 7 months after the last dose of study drug to minimize the risk of pregnancy
- Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 4 months following the last dose of study drug.
Exclusion Criteria:
- A medical history of prior anti-cancer treatment for pancreatic cancer.
- Locally advanced unresectable disease or evidence of metastatic disease.
- Any other invasive malignancy within the past three years.
- Presence of any known contraindications to or hypersensitivities to the investigational products.
- Use of strong CYP3A4 inhibitors or inducers which cannot be discontinued prior to study entry.
- A non-surgical candidate.
- Subject is unable to understand, provide consent or comply with study requirements, treatments or instructions in the opinion of the treating physician.
- Uncontrolled diarrhea, active infection, known interstitial lung disease or other medical condition that precludes safe administration of this combination therapy consistent with manufacturer recommendations.
- Unwilling/unable to comply with birth control requirements while on study.
- Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 7 months for females and 4 months for males after the last dose of study drug.
- Females who are pregnant or breastfeeding.
- History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
- Prisoners or subjects who are involuntarily incarcerated.
- Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
- Subjects demonstrating an inability to comply with the study and/or follow-up procedures.
- Known dihydrypyrimidine (DPD) deficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Liposomal irinotecan with FOLFOX
Subjects will receive 8 cycles and each cycle is 14 days.
|
Subjects will receive 60 mg/m2 intravenously on Day 1 of each 14 day cycle.
Other Names:
Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
30 day post operative complication rate
Time Frame: 30 days
|
To determine the 30 day post operative complication rate, as measured by hospital readmission, death, second surgery or interventional procedure, or major complications extending hospital stay
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Completion Rate
Time Frame: 4 months
|
To determine the treatment completion rate of therapy, as defined by the percentage of subjects that completed all intended cycles
|
4 months
|
Rate of complete surgical resection
Time Frame: 7 months
|
To determine the rate of complete surgical resection (R0)
|
7 months
|
Objective Response Rate
Time Frame: 5 months
|
To determine radiographic objective response rate of the primary tumor as measured by RECIST v 1.1 criteria
|
5 months
|
Biochemical Response Rate
Time Frame: 9 months
|
To determine the biochemical response rate and pattern of response as measured by serial CA 19-9 levels
|
9 months
|
Patient-Reported Quality of Life
Time Frame: 9 months
|
To determine the patient-reported quality of life during treatment as measured by the NCI validated FACT-G survey
|
9 months
|
Rate of other pathologic downstaging
Time Frame: 7 months
|
To determine the rate of other pathologic downstaging
|
7 months
|
To determine the safety of liposomal irinotecan in combination with 5-fluorouracil, oxaliplatin, and leucovorin as assessed by the number of treatment-related adverse events as assessed by CTCAE v 4.0
Time Frame: 9 months
|
9 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Thomas George, MD, University of Florida
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UF-STO-PANC-004
- IRB201800866 -A (Other Identifier: University of Florida)
- OCR16281 (Other Identifier: UF OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Adenocarcinoma
-
Fudan UniversityUnknownStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Scandion Oncology A/SAlcedis GmbHRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Inoperable Disease | Localized Pancreatic AdenocarcinomaDenmark, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
Jean-Luc Van LaethemCelgene CorporationCompletedPancreatic Adenocarcinoma Resectable | Pancreatic Adenocarcinoma Metastatic | Pancreatic Adenocarcinoma Locally AdvancedBelgium
Clinical Trials on Liposomal Irinotecan
-
Nelson YeeIpsenActive, not recruitingLocally Advanced Pancreatic Carcinoma(LAPC)United States
-
Reema A. PatelRecruitingColorectal Cancer | Pancreatic CancerUnited States
-
University of California, San FranciscoCompletedGlioblastoma | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic OligodendrogliomaUnited States
-
Emory UniversityIpsen; Taiho Oncology, Inc.RecruitingGastric Adenocarcinoma | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IV Gastric Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage... and other conditionsUnited States
-
Washington University School of MedicineMerck Sharp & Dohme LLC; IpsenWithdrawnTriple Negative Breast Cancer | Brain MetastasesUnited States
-
Hebei Medical University Fourth HospitalNot yet recruiting
-
AIO-Studien-gGmbHServier Deutschland GmbH; Crolll GmbhActive, not recruitingMetastatic Pancreatic Cancer | Locally Advanced Pancreatic CancerGermany
-
University of Southern CaliforniaNational Cancer Institute (NCI); IpsenWithdrawnGastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Locally Advanced Unresectable Gastric Adenocarcinoma | Metastatic Unresectable Gastric AdenocarcinomaUnited States
-
University of Wisconsin, MadisonIpsenRecruitingMetastatic Colorectal CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant Solid NeoplasmUnited States